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1. Introduction
Lipid  nanoparticles  (LNP)  are  invaluable  carriers  for  drug and gene  delivery,  and they
are classified as cationic,  neutral  and anionic  depending on the electronic  charges exist‐
ing on the surface of the vesicles [1]. These charges are originated from the charged lip‐
ids from which lipid nanoparticles are formulated. Cationic LNP are commonly used for
DNA or RNA carriers  due to  their  interaction with negatively-charged nucleotide.  Both
neutral and negatively-charged LNPs are used for drug delivery [2] and may be formu‐
lated  as  sterically  stable  LNPs  (SSLNPs),  which  are  amendable  for  cell  type-specific  or
tissue-specific  targeting  delivery  [3].  For  liver  drug  delivery,  tremendous  efforts  have
been made to  develop cell  type-selective  lipid-based drug carriers.  Effective  approaches
in  targeting  hepatocytes,  Kupffer  cells  and hepatic  stellate  cells  have  been evaluated in
small  animals  [3,  4],  and some of  them may be  translational  to  clinical  application  [5].
These approaches are referable when cationic LNPs are considered for cell type-selective
gene delivery. A prerequisite for the success of gene therapy for liver disorders is the de‐
velopment  of  powerful  gene  carriers.  Non-viral  vectors  have  been  very  successful  for
gene  transfer  in  an  in  vitro  setting,  in  terms of  efficiency of  lipofection,  applicability  in
variety of cell types, and amending ability of cell type-specific delivery (Fig. 1). The clini‐
cal application of LNP-mediated gene transfer has been hampered by low efficiency, in‐
stability  in  the  bloodstream,  short-term  transgene  expression  and  toxicity.  These
shortcomings are the bottle neck hindering the gene transfer employing LNPs as carriers
for  delivery of  function gene(s)  to  solid organs,  and are the challenges in moving from
small  to  large animals  of  potential  gene carriers  and approaches,  and in the translation
to clinical  application.  However,  the polylipid nanoparticles (PLNP) we have developed
over the past decade represent one of the few formulations that are applicable for in vivo
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gene transfer [6], due to a high DNA-packaging capacity, an extremely low binding rate
to serum proteins, low toxicity, and amendable synthetic approaches [7,  8].  This chapter
intends to introduce the characteristics of  this formulation,  and to discuss our efforts in
moving the non-viral gene transfer platform from small to large animals towards clinical
applications.
Figure 1. In vivo gene transfer mediated by viral or non-viral vectors. Viral vectors, such as lentiviral or retroviral
vectors, which lead to integration of transgene in the host genome, give rise to long-term transgene expression. How‐
ever, they may cause insertion-induced mutation that is oncogenic. Adenoviral or adeno-associated viral (AAV) vectors
often yield a high level of transgene expression in host organs. However, generation of antibodies against viral com‐
ponents is still a concern. Non-viral gene transfer may be achieved by direct plasmid administration with local electro‐
poration or a hydrodynamic approach. The latter is only applicable in mice. Lipid nanoparticle (LNP)-mediated gene
transfer becomes a useful approach which is often very successful for in vitro gene transfer. Few formulations of cati‐
onic LNPs are valuable for in vivo gene transfer. There has been a still demand in improving their in vivo stability and
gene transfer efficacy.
There are a number of critical components for a potential gene therapy product to move
from one step to the next in this pipeline. Promisingly, LNP-mediated gene transfection for
the treatment of genetic and metabolic disorders or tumors has been moved to clinical trial
phases (http://clinicaltrials.gov). A phase I pilot study of gene therapy for cystic fibrosis us‐
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ing cationic liposome-mediated gene transfer (NCT00004471) has been completed. A phase I
trial of intratumoral epidermal growth factor receptor (EGFR) antisense DNA delivered by
DC-Chol liposomes in advanced head and neck cancer, including oral squamous cell carci‐
noma (NCT00009841) and DOTAP-Chol-Fus1 liposome-mediated gene therapy for non-
small cell lung cancer (NCT00059605] [9] were conducted respectively by University of
Pittsburg and MD Anderson Cancer Center in collaboration with the National Cancer Insti‐
tute (NCI). Fus1 is a tumor suppressive gene that has been shown to be effective in sup‐
pressing the growth of original or metastatic lesions of non-small lung cancer when it is
delivered locally or systemically [10]. Thus, it appears that genetic therapy using LNPs as
gene carriers has the potential to be specially tailored for genetic disorders or cancers.
2. Nanoparticle carriers for drug or gene delivery
Lipid-based gene carriers include liposomes (cationic or anionic), polymer and dendrimer
nanoparticles.  Cationic liposomes are capable of delivering genes to cells or tissues,  and
achieving maximal therapeutic efficiency with minimal adverse effects [1].  However,  the
use  of  cationic  LNPs for  in  vivo  DNA transfection is  hindered by substantial  problems;
i.e.  after  intravenous  administration,  cationic  LNPs  bind  to  plasma  protein  and  blood
cells  due  to  charge  reaction.  The  resulting  aggregates  of  carriers  with  proteins  or  cells
block microcirculation or may be cleared rapidly [11,  12].  The common formulations for
in vivo  gene delivery are DOTMA or DOTAP-DOPE or DOTAP-cholesterol (Chol). These
formulations  are  highly  serum-reactive  [6,  13].  Lungs  are  the  major  organ shown to  be
highly transfected probably due to the accumulation of aggregates of lipoplexes with se‐
rum proteins or blood cells when the lipoplexes are administrated intravenously [14]. For
this reason, cationic LNPs were once used widely for gene delivery to the lungs; and lat‐
er  for  treating lung cancers  and metastasis  with  further  optimization [10,  15,  16].  LNP-
mediated gene delivery to the liver is more difficult than to lungs. For the development
of  the  gene  carriers,  cationic  LNP  formulations,  such  as  DC-Chol,  DOTAP-Chol,  are
available for delivering genes to various tissues [17].  A few LNP formulations targeting
hepatocellular  carcinoma  (HCC)  have  been  developed  for  improving  efficacies  of  drug
therapy [18,  19].  In order to avoid the rapid clearance by the reticuloendothelial  system
(RES) and to increase the drug delivery through the enhanced permeability and retention
(EPR) effect to a tumor site by passive targeting, novel strategies, such as reducing parti‐
cle size, minimizing rigidity of lipids, generating amphiphilic vesicles and shielding from
the  recognition  by  RES  system,  have  been  attempted  in  formulating  lipid-based  drug/
gene  carriers  [1,  2].  To  reduce  lysosomal  degradation,  pH-sensitive  LNPs  are  prepared
for drug or gene delivery [20]. These approaches may be instructive in the development
of LNPs for gene transfer at different stages of preclinical translation.
Polymeric non-viral vectors have exhibited additional advantages of lower toxicity and im‐
munogenicity [21, 22]. These vectors may offer the possibility of industrial production fol‐
lowing good manufacturing practice (GMP). Amphiphilic polyethylene glycol (PEG) has
been engineered as a linker, most for coupling peptides to cationic lipids. Other polymers,
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such as dendritic poly(L-lysine)-b-poly(L-lactide)-b-dendritic vector [23], poly (ethylenei‐
mine) (PEI) [24], poly (methacrylate) [25] and polyamidoamine dendrimers [26], have been
demonstrated to be effective for in vitro gene delivery. However, striking issues still exist for
cationic polymers regarding whether they are applicable for in vivo gene transfer to solid or‐
gans such as the liver, without significant adverse effects.
3. Liver-specific gene delivery
Because of our interest in gene therapy of liver disorders, we have focused our efforts on
improving  liver-based  gene  delivery.  The  pathogenesis  of  liver  injury  and  fibrosis  in‐
volves complicated interactions among different cell populations in the liver, soluble fac‐
tors,  such  as  cytokines  and reactive  oxygen  species  (ROS),  and the  extracellular  matrix
components. In order to improve the efficacy in preventing hepatocellular injury, the use
of LNPs that are capable of delivering hepatoprotective agents to the liver, selectively to
hepatocytes, will increase local concentration of therapeutic agents, reduce adverse effects,
and achieve maximal therapeutic efficiency. The parenchymal cell type in the liver is hep‐
atocytes, which are responsible for an array of metabolic function in the body and are of‐
ten  damaged  in  a  variety  of  pathological  processes.  The  asialoglycoprotein  receptor
(ASGP-R)  on mammalian hepatocytes  provides  a  unique means for  the  development  of
liver-specific  drug  or  gene  carriers.  The  abundant  receptors  on  hepatocytes  specifically
recognize the natural ligands, lectin and asialofetuin (AF), as well as those with terminal
galactose or N-acetylgalactosamine residues, and hepatocytes endocytose these ligands for
an intracellular degradation process [27,  28].  The use of  its  natural  or  synthetic  ligands,
such as  galactosylated cholesterol,  glycolipids  or  galactosylated polymers  to  label  LNPs
has achieved significant targeting efficacy to the liver [4, 28]. AF-labeled LNPs have been
used for improving liver-targeting gene transfer in small animals [29], yet there have not
been successful reports available in the translation to large animals, such as pigs [30]. In‐
stead, plasmid DNA was directly administrated into the hepatic vein through a catheter
with a balloon closure of hepatic vein blood flow [30]. One particular attention has been
drawn in terms of the use of AF-labeled drug carriers for HCC targeting. The expression
of ASGP-R in HCC cells varies depending on the differentiation status of HCC cells [31].
In general, well-differentiated HCC usually expresses relatively high levels of hepatocyte-
specific genes,  including ASGP-R; whereas poorly-differentiated HCC expresses minimal
or no hepatocyte-specific genes, including ASGP-R [32]. In most cases, there exists the dra‐
matic heterogeneity of liver-specific gene expression in human HCC tissues [33], and de‐
creased expression of ASGP-R was observed in liver cancer tissue [34].  Therefore,  using
AF or other galactosylated or lactosylated residues to label LNPs for drug or gene deliv‐
ery may not always be effective for patients with HCC, because HCC develops on a varie‐
ty of disease backgrounds and there is a striking variation in ASGP-R expression levels in
HCC  from  different  patients.  Using  well-differentiated  hepatoma  cells,  such  as  HepG2,
Hep3B and Huh-7 cells, as an in vitro screening tool may not necessarily reflect targeting
efficacy to tumor-specific distribution in vivo [35].
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High density lipoprotein (HDL) has a high drug carry capacity, and can be recognized by
HDL receptors on hepatocytes. Recombinant HDL was utilized to deliver an anti-HBV pep‐
tide (nosiheptide) to the liver, and it was shown to achieve a selective distribution in hepato‐
ma cells in vitro and a preferential liver distribution in rats [36]. Apolipoprotein E is cleared
by hepatocytes, and it has been employed to be carriers for small interfering RNA (siRNA)
delivery to hepatocytes [37].
Given the fact that hepatic stellate cells (HSCs) are the major cell type responsible for hepatic
fibrosis, a repairing process that causes excess production of extracellular matrix compo‐
nents and deposition of fibrotic scaring in chronically injured liver [38], much attention has
been focused on targeting this cell type in the last decade. A couple of cell surface molecules
that are overexpressed on activated HSCs during hepatic fibrogenesis, such as insulin
growth factor receptor II [39], collagen type VI and platelet-derived growth factor (PDGF)
receptor β-subunit [40] are selected as the cell surface targets. Drug carriers labeled with
specific peptides recognizing these cell surface molecules, such as cyclic peptide containing
arginine-glycine-aspartate (RGD)-labeled sterical lipid nanoparticles [3] or Mannose-6-phos‐
phate human serum albumin (M6P/HAS) [41] exhibited HSC-selective distribution. The
RGD cyclic peptide was recently used as a targeting molecule for the recognition of activat‐
ed HSCs in two animal models for early diagnosis of hepatic fibrosis with a SPECT imaging
modality [42]. Using the retinol binding protein (RBP) in activated HSCs seems to be very
effective in delivering siRNA against gp46 (rat homolog of human heat shock protein 47),
and inhibiting fibrosis in two animal models [43].
Targeting approaches for drug or gene delivery to other non-parenchymal cell types, such as
Kupffer cells or sinusoidal endothelial cells, are summarized recently [27]. These approaches
are crucial in delivering agents which are anti-inflammatory or anti-oxidants to these cell
types due to the fact that Kupffer cells are pivotal in the mediation of inflammatory respons‐
es and subsequent fibrogenesis [44].
4. Polylipid nanoparticle-mediated liver gene delivery
Compared to drug delivery, LNP-mediated in vivo gene delivery is still in its development
stage; and many issues that affect delivery approaches and efficacy remain to be solved. The
main issues include: 1) the formation of aggregates between cationic lipids and serum pro‐
teins bearing negative charges; 2) the administration routes of LNP-DNA complexes (lipo‐
plexes); 3) intracellular trafficking from the cytoplasm to the nucleus; 4) the proliferative
state of cells to be transfected; and 5) transient transgene expression for a short duration [6,
45]. Substantial efforts have been made to address these issues in our previous studies and
by others [8, 46, 47]. Particularly, we polymerized an acrylamide lipid to generate a polyca‐
tionic lipid (PCL), which was able to interact with plasmid DNA effectively and form com‐
pacted complexes as demonstrated by Raman microspectral analysis [8]. PCL has a unique
molecular configuration and molecular weight distribution as indicated by mass spectro‐
photometrical analysis [8]. Moreover, this lipid can be synthesized in a multiple gram quan‐
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tity in a laboratory, and the synthetic approach is amendable for industrial production at a
quantity sufficient enough for large animal use [8]. PLNP was formulated with a neutral lip‐
id, cholesterol. The PLNP size was reduced to approximately 100 nm in diameter [7], and
the Zeta potential of PLNP was decreased to neutral by neutralizing extra-positive charges
with excess plasmid DNA [8]. Not only was this formulation of PLNP non-toxic, but it also
displayed transfection efficiency equivalent to other commercially available transfection
agents, such as Lipofectamine in hepatoma cell lines [7]. Moreover, high-resolution fluores‐
cent deconvolution microscopy documented that PLNP-mediated gene transfection led to
earlier GFP expression in hepatoma cells than Lipofectamine [8]. The unique feature of this
formulation is that it is extremely serum-resistant, and exposure to cell culture medium con‐
taining 50% fetal bovine serum for 24 hours did not affect its size significantly. PLNP react‐
ed up to 30-fold less with serum proteins or blood cells after intravenous administration in
comparison with DOTAP-DOPE or DOTAP-Chol formulations [6]. This feature makes
PLNP formulation particularly useful for in vivo gene transfer. In the subsequent studies, we
have proved that it is very effective in the transfer of reporter genes or function genes to
normal mouse livers as demonstrated in Fig. 2 by bioluminescent imaging of firefly lucifer‐
ase gene expression 24 hours after portal vein injection of PLNP-plasmid DNA complexes
(polyplexes) or preclinical models [48, 49].
Figure 2. PLNP-mediated gene transfer into mice through portal vein injection. One day after the intravenous injec‐
tion of polyplexes with pNDLux.2 plasmid encoding the firefly luciferase gene, the animal was imaged by CCD camera. The
expression of luciferase was clearly shown in the liver area, demonstrating the effectiveness of this delivery approach and
the applicability of a non-invasive imaging modality in the determination of transgene expression in animals.
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We also developed an approach to promote normal hepatocytes to proliferate in situ without
partial hepatectomy, which favors the transgene expression by lipofection but is not accepta‐
ble for clinical application [6]. Furthermore, placing an indwelling catheter in the portal vein
allows repeated administration of polyplexes for sustained transgene expression [6]. All
these efforts render our formulation of PLNP distinct from other lipid-based nanoparticles.
Our animal experiments have clearly demonstrated that PLNP is characterized as extremely
stable in the bloodstream, and highly effective in liver-based gene transfer when polyplexes
are administrated through the portal vein [6, 17]. In comparison with other commonly used
lipid formulations of nanoparticles, our formulation possesses the notable advantages essen‐
tial for in vivo gene delivery as illustrated in Table 1.
Characteristics PCL PLNP Lipofectamine DOTAP-Chol
Cationic lipid Yes LNP LNP LNP
Particle size
(nm) Irrelevant 125±54 358 ±85 110±20
Size changes(50%FBS) Irrelevant 100±20nm 2206 ± 311 nm 1050±100 nm
In vitro transfection
efficiency Luciferase activity
(in RLU)
Irrelevant >10E7 >10E7 >10E7
Cytotoxicity (LDH release) Low or none Normal 10±3%(>5%)
11±3.5%
(>5%)
Binding rate to serum
protein Low Low Obvious
20-30-fold higher than
PLNP
In vivo stability Irrelevant Stable Not determined Instability
Usage Raw material for
PLNP
In vitro or in vivo
transfection In vitro transfection In vivo transfection
The content in this table was summarized according to our previous publications [6-8]. FBS = fetal bovine serum. RLU =
relative light unit. LDH = lactate dehydrogenase.
Table 1. Comparison of common transfection agents for in vitro and in vivo application
5. Preclinical trials for proof of the concept
In order to demonstrate that our PLNP formulation is effective in delivering functional
genes to the liver, we established a liver injury model in mice caused by the treatment with
D-galactosamine (D-Gal) and lipopolysaccharide (LPS). This combination of D-Gal/LPS
treatment resulted in a profound acute liver injury characterized by massive liver cell death
through apoptosis, elevation of serum alanine aminotransferase (ALT), significant oxidant
stress, depletion of the reduced form of glutathione and enhanced lipid peroxidation [50]. In
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separate studies we have demonstrated that anti-oxidant enzyme such as extracellular su‐
peroxide dismutase (EC-SOD), SOD mimetics (MnTBAP) and catalase are effective in the
prevention of hepatic toxicity caused by xenobiotics in primary hepatocytes or hepatoma
cells [51-53], and they improved recipient survival and graft function and growth after
small-for-size liver transplantation in rats [54]. Therefore, we chose the human EC-SOD
gene as a functional gene to prove the feasibility. The EC-SOD gene product was exclusively
secreted into the extracellular space and functions as an ROS scavenger. ROS are generated
in both intracellular and extracellular spaces, and superoxide anions and hydrogen peroxide
(H2O2) are able to cross the plasmatic membrane to enter the extracellular space [17]. It was
found that two days after portal vein injection of EC-SOD polyplexes, liver EC-SOD gene
expression was increased approximately 50-fold compared to the group receiving injection
of control plasmid polyplexes, and serum SOD activity was increased accordingly. On the
other hand, serum ALT was reduced to nearly one third in mice receiving EC-SOD polyplex
injection compared to those with D-Gal/LPS challenge, along with improved liver histology,
restored glutathione levels and decreased lipid peroxidation [48]. The findings of this pre‐
clinical trial confirmed the effectiveness of PLNP-mediated EC-SOD gene delivery to the liv‐
er, and that the delivery protected the mice from oxidant stress-associated liver injury. The
results also indicate that this anti-oxidant gene delivery approach could be useful in attenu‐
ating xenobiotics or drug metabolite-induced toxicity to the liver.
Ischemia/reperfusion (I/R)-associated donor organ damage is inevitable in all solid organ
transplantation,  and is  caused by enhanced oxidant  stress  with  release  of  inflammatory
cytokines, such as tumor growth factor-α (TNF-α) and interleukin 2 (IL-2). Although the
precise molecular mechanism of the I/R-associated liver injury remains to be investigated,
enhanced oxidant  stress  with release of  superoxide anions or  H2O2,  depletion of  the re‐
duced form of glutathione and increased lipid peroxidation has been the key element in
the pathogenesis in orthotopic liver transplantation (OLT) or small size liver graft trans‐
plantation (SSLGT) [54-56]. Thus, it is rational to use of antioxidant gene transfer to mini‐
mize  oxidant  stress  and  improve  the  donor  organ  quality  and  function  after  the
implantation.  We  delivered  either  EC-SOD,  catalase  gene  or  in  combination,  using  the
same approach as described above. Two days after the delivery, the transgene expression
was increased for 10-50-fold, with increased SOD or catalase activity in the mouse liver.
This delivery led to a marked decrease in superoxide anion levels and H2O2 release along
with a decrease in serum ALT levels, liver lipid peroxidation and dramatic improvement
of liver histology [49]. This study was positively commented by two well-known hepatol‐
ogists  from Europe as  an editorial,  quoting “beyond a proof  of  the principle,  the study
could be the basis for studies with larger animals and may help bridge the gap between
the basic understanding of pathophysiologic processes in animal models towards a practi‐
cal clinical application in liver transplantation” [57]. The findings are especially applicable
in living donor liver transplantation,  for which small  or margin donor livers were used
for transplantation. Much more pronounced oxidant stress, a higher rate of graft failure,
and retarded graft growth are found in small size liver transplantation than OLT [54, 58].
The margin grafts with small  size or steatosis and fibrotic deposition are often used for
transplantation in clinics due to severe shortage of donor organs.
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6. Challenges in scaling-up and moving towards clinical applications
Our preclinical studies were performed in mice, and there are certainly a number of issues
to face when this anti-oxidant gene therapy approach is considered to be evaluated in mid‐
dle or large size animals such as rabbits, dogs, monkeys or pigs. The first issue is to scale-up,
which includes the plasmid DNA generation, synthesis of PCL in a quantity, and formula‐
tion of PLNP at a volume sufficient enough for the use in large animals. More challenges
exist regarding how to stimulate liver cells to proliferate in large animals and deliver poly‐
plexes locally to the liver. Using a catheter through the femoral vein or jugular vein for ret‐
rograde administration into hepatic vein or passing into the portal vein for administration
similar to the transjugular intrahepatic portosystemic shunt (TIPS) procedure, which is used
to lower portal hypertension in cirrhotic patients, should be feasible in large animals when
angiography and the administration are performed by an experienced specialist with the
availability of angiographic devices. The latter method was used to administer adenoviral
vector in baboons [59]. One trial of plasmid DNA injection into the hepatic vein by blocking
the hepatic vein out-flow with an inflated balloon achieved high gene expression levels in
selected pig liver lobes [30]. Safety concerns include amount of polyplexes to be administrat‐
ed locally and the effects of the plasmid DNA, PLNP and polyplexes on the liver as well as
systematically. LNP-mediated gene transfer is usually transient; therefore, there will be less
concern for long-term effects of the transgene products on the host. However, immune reac‐
tion to human gene products in animals may occur if the transgene products are produced
at sustained levels for a long period of time. It is preventable by administration of immuno‐
suppressive agents, such as FK506. Moreover, innate immunity to plasmid DNA with bacte‐
rial unmethylated CG dinucleotide (CpG) can be eliminated by using CpG-free plasmid [60].
An additional concern is to establish a liver injury model to evaluate the effect of anti-oxi‐
dant gene transfer by PLNP in large animals. For pigs, exposure to a loading dose of 0.25
g/kg, maintaining the blood concentration of acetaminophen at 350-450 mg/dl, and adapting
enteric maintenance dose of 1,000-3,000 mg/hour resulted in the onset of acute liver failure
(prothrombin time value <30%) within 32±4.4 hours, and further mortality in 15.8±2.4 hours
[61]. A large dose of acetaminophen intake causes significant oxidant stress and acute liver
injury due to its metabolism and generation of an interactive metabolite, n-acetyl-p-benzo‐
quinone imine (NAPQI), which binds to the cytoplasmic membrane, leads to lipid peroxida‐
tion, depletion of antioxidants, such as glutathione, and results in hepatic injury. Not only
will the delivery of antioxidant genes with PLNP in a pig model of liver injury assess the
therapeutic efficacy, but also take advantage of a regenerative response to the injury for high
transgene expression. Alternatively, small size graft liver transplantation (SSGLT) at ≤50%
graft volume could be performed in rabbits or pigs to mimic living donor liver transplanta‐
tion in humans. Significant oxidant stress-associated injury and regenerative response in the
small size grafts will be the best fit for the high transgene expression and ROS scavenging
property of the gene product. Therefore, SSGLT may be considered to be a valuable model
for evaluating the feasibility and efficacy of anti-oxidant gene transfer for small-for-size-as‐
sociated graft failure in a transplant setting.
Polylipid Nanoparticle, a Novel Lipid-Based Vector for Liver Gene Transfer
http://dx.doi.org/10.5772/54270
99
In summary, moving promising PLNP-mediated antioxidant gene transfer from small ani‐
mals to large animals may face more challenges than discussed above, and it is even more
challenging when further considering for clinical use, in terms of safety concern and admin‐
istrative approval. Fig. 3 provides a schematic illustration of the roadmap from bench to
bedsides of a potential biological therapy. The reality is that with limited funding opportu‐
nities from governmental or private agencies, to cope with multi-facet challenges at a large
scale, it is less likely to reach the final goal in a short term. Attracting financial investments
and taking advantages of cutting-edging technologies and vast resources from biopharma‐
ceutical companies may advance this process in a fast pace. In this context, the net benefits
would be the early clinical application of this promising antioxidant gene transfer in pa‐
tients with critical needs and the financial return from the investment. We would foresee
such a movement occurring in the near future.
Figure 3. Translation roadmap of a potential gene therapy platform from bench to bedside. This illustration
summarizes the major steps in moving a potential gene transfer approach from laboratory research to clinical trials.
The actual actions could be more complicated than described. However, for the guarantee of patient safety, each new
therapeutic agent must be well characterized, and evaluated in preclinical settings, and then move to large animals
for feasibility assessment. The balance between therapeutic benefits and potential risks of an innovative therapy plat‐
form always leans on the patient safety as the first priority.
7. Conclusion and prospectives
Non-viral vector-mediated gene transfer has less concern in terms of integration-associated
long-term transgene expression and insertion-induced mutation. In general, non-viral vector
elicits minimal immune responses in contrast to adenoviral vectors [17]. However, non-viral
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vectors, such as lipid nanoparticles (LNPs) possess their own drawbacks when they are con‐
sidered for in vivo use. One prominent issue is the interaction of cationic LNPs with serum
protein and blood cells, and this causes a series of issues, such as instability of the lipoplexes
or polyplexes and adverse effects to the host, including non-preferential distribution, embo‐
lism of the aggregates of lipoplex-protein or blood cells, and inflammatory responses. For
these reasons, many gene transfer agents are very effective in cell culture; whereas they have
less applicability in vivo. Up to date, only a few formulations of cationic LNPs have proved
to be effective and safe in animals and have reached the stage of clinical trials, such as DO‐
TAP-Chol and DC-Chol. Our PLNP formulation has a superior stability profile, and dis‐
played much less reactivity to serum proteins and blood cells when compared to other
commercially available formulations. At the same time, it has proved to be the most effec‐
tive liver-based gene transfer agent [6]. Two preclinical trials with different models of oxi‐
dant-stress-associated liver injury have demonstrated the effectiveness of the anti-oxidant
gene delivery in the liver, and the efficacy of the gene delivery in minimizing oxidant-stress,
attenuating liver cell death, and improving liver histology [48, 49]. Further efforts have been
made to move this promising PLNP-mediated anti-oxidant gene transfer technology from
bench to bedside. The strategies in pushing this movement towards clinical trials include: 1)
Scaling-up of the polycationic lipid production and generation of PLNPs; 2) Generation of
specific antioxidant gene plasmids in a GMP facility at the standard for clinical use; 3) Estab‐
lishing large animal models for safety and efficacy assessment; and 4) Preparation for ob‐
taining administrative approval of clinical application. Although the clinical translation of
this potential technology will need tremendous efforts, we anticipate that this technology
will eventually reach to patients with critical needs as a novel therapy. Potential indications
which may benefit from this therapy range from alcohol or drug toxicity to living donor liv‐
er transplantation with a margin graft. This technology is also applicable in oxidant stress-
associated disorders in other systems, such as ischemic cardiac, pulmonary, brain or renal
damage, etc. [17]. With the combination of our extensive expertise in drug and gene deliv‐
ery, advanced knowledge and skills in liver injury, fibrosis, transplant and cancer research
and practice, in addition to the engine of financial investment from various sources, such as
venture capital and governmental support in entrepreneurship, we are optimistic to foresee
the benefits of this technology in indicated patients in a near future. Nevertheless, the road
to reach this goal will not be smooth, and various challenges demand powerful solutions.
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